Related references
Note: Only part of the references are listed.Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) -: Results of a phase II study
Samy Louafi et al.
CANCER (2007)
Prospective randomised phase II study of gemcitabine at standard or fixed dose rate schedule in unresectable hepatocellular carcinoma
Z Guan et al.
BRITISH JOURNAL OF CANCER (2003)
A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma
CS Fuchs et al.
CANCER (2002)
Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial
TS Yang et al.
ANNALS OF ONCOLOGY (2002)
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer
P Bhargava et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel
R Bruno et al.
INVESTIGATIONAL NEW DRUGS (2001)
Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine
H Ulrich-Pur et al.
ONCOLOGY (2001)
Share Paper
